BR112021009869A2 - Óleo de canábis em pó formulado por nano-emulsificação catiônica, métodos de produção e usos deste - Google Patents

Óleo de canábis em pó formulado por nano-emulsificação catiônica, métodos de produção e usos deste

Info

Publication number
BR112021009869A2
BR112021009869A2 BR112021009869A BR112021009869A BR112021009869A2 BR 112021009869 A2 BR112021009869 A2 BR 112021009869A2 BR 112021009869 A BR112021009869 A BR 112021009869A BR 112021009869 A BR112021009869 A BR 112021009869A BR 112021009869 A2 BR112021009869 A2 BR 112021009869A2
Authority
BR
Brazil
Prior art keywords
production methods
oil powder
emulsification
cannabis oil
powder formulated
Prior art date
Application number
BR112021009869A
Other languages
English (en)
Portuguese (pt)
Inventor
Ezra Rafael
Larush Liraz
Magdassi Shlomo
Original Assignee
Karnak Tech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karnak Tech Llc filed Critical Karnak Tech Llc
Publication of BR112021009869A2 publication Critical patent/BR112021009869A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112021009869A 2018-08-13 2019-03-11 Óleo de canábis em pó formulado por nano-emulsificação catiônica, métodos de produção e usos deste BR112021009869A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL261132A IL261132A (en) 2018-08-13 2018-08-13 Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
PCT/IL2019/050268 WO2020035850A1 (en) 2018-08-13 2019-03-11 Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof

Publications (1)

Publication Number Publication Date
BR112021009869A2 true BR112021009869A2 (pt) 2022-05-17

Family

ID=63998426

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021009869A BR112021009869A2 (pt) 2018-08-13 2019-03-11 Óleo de canábis em pó formulado por nano-emulsificação catiônica, métodos de produção e usos deste

Country Status (9)

Country Link
US (2) US11712430B2 (https=)
EP (1) EP3716946A1 (https=)
JP (1) JP2021535935A (https=)
CN (1) CN113473965A (https=)
AU (1) AU2019322212B2 (https=)
BR (1) BR112021009869A2 (https=)
CO (1) CO2021007647A2 (https=)
IL (2) IL261132A (https=)
WO (1) WO2020035850A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020220141A1 (en) * 2019-05-02 2020-11-05 Betterlife Pharma Inc. Cannabinoid stock transdermal formulations
US10780075B1 (en) 2019-07-31 2020-09-22 Etain IP, LLC Water soluble cannabis composition
AU2020330527A1 (en) * 2019-08-12 2022-02-24 Tenshi Kaizen Private Limited Cannabidiol orally disintegrating tablets
CA3166084C (en) 2020-07-29 2025-06-10 Karnak Technologies, Llc Oral compositions of beneficial lipophilic, nutriceutical, and edible oil food supplements
AU2021317264A1 (en) * 2020-07-29 2022-09-22 Karnak Technologies, Llc Improved formulations of lipophilic subtances for cosmetic uses
US20230270678A1 (en) * 2020-07-29 2023-08-31 Karnak Technologies, Llc Pharmaceutical compositions for improved delivery of therapeutic lipophilic actives
EP4196112A4 (en) * 2020-08-14 2024-10-16 Capheads LLC CANNABIS-DERIVED RESIN DOSING CAPSULE AND METHOD FOR THE PRODUCTION THEREOF
CA3114085A1 (en) * 2021-04-05 2022-10-05 MEC11S Inc. Composition comprising cannabis extracts and method of manufacturing same
JP2023010676A (ja) * 2021-07-09 2023-01-20 株式会社東洋新薬 固形組成物
US20240415854A1 (en) 2023-06-16 2024-12-19 Miles J. Terry Process for creating a cannabinoid pico-emulsion with antibiotic properties and the resulting pico-emulsion
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles
WO2026037496A1 (en) * 2024-08-14 2026-02-19 Tetra Pharm Technologies A self-emulsifying solid composition comprising a cannabinoid

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130102591A1 (en) * 2010-01-26 2013-04-25 Andrew Lurie Salzman Compositions and methods for prevention and treatment of pulmonary hypertension
US8629177B2 (en) * 2010-08-24 2014-01-14 Aphios Corporation Nanoencapsulated delta-9-tetrahydrocannabinol
DK2804587T3 (da) 2012-01-19 2019-08-12 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed
WO2013172999A1 (en) 2012-05-16 2013-11-21 Mewa Singh Pharmaceutical compositions for the delivery of substantially water-insoluble drugs
US10213391B2 (en) 2014-05-06 2019-02-26 Mewa Singh Pharmaceutical compositions comprising hemp and turmeric to treat pain and inflammation
US20160058866A1 (en) 2014-09-02 2016-03-03 Ronald D. Sekura Alternative solutions for the administration of cannabis derived botanical products
US9629886B2 (en) 2015-02-24 2017-04-25 Ers Holdings, Llc Method for conducing concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages and resulting powderized cannabis oil
AU2016231788A1 (en) 2015-03-19 2017-10-12 One World Cannabis Ltd Preparations of cannabis emulsions and methods thereof
CA2986268C (en) * 2015-05-28 2024-01-02 Insys Development Company, Inc. Stable cannabinoid formulations
BR102015024165A2 (pt) * 2015-09-18 2017-03-28 Prati Donaduzzi & Cia Ltda composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
EP3368014B1 (en) * 2015-10-26 2023-10-04 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd Novel cannabinoid formulations
EP3442522A4 (en) 2016-04-15 2020-01-01 SRE Wellness, Inc. METHOD FOR PRODUCING HYDROPHILIZED CANNABI OIL USING EMULSIFIERS AND RELATED CANNABINOID COMPOSITIONS
EP3558297A1 (en) * 2016-12-20 2019-10-30 Tilray, Inc. Novel cannabinoid compositions and methods of treating pediatric epilepsy
CO2017007962A1 (es) * 2017-08-04 2018-04-19 Alsec Alimentos Secos S A S Nanoparticulas oleosas de cannabis microencapsuladas en polvo

Also Published As

Publication number Publication date
US20210059975A1 (en) 2021-03-04
CA3086887A1 (en) 2020-02-20
AU2019322212B2 (en) 2022-09-29
WO2020035850A1 (en) 2020-02-20
IL275430A (en) 2020-08-31
EP3716946A1 (en) 2020-10-07
IL261132A (en) 2018-11-04
US20230321031A1 (en) 2023-10-12
JP2021535935A (ja) 2021-12-23
CO2021007647A2 (es) 2021-08-30
US11712430B2 (en) 2023-08-01
AU2019322212A1 (en) 2021-04-08
CN113473965A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
BR112021009869A2 (pt) Óleo de canábis em pó formulado por nano-emulsificação catiônica, métodos de produção e usos deste
CR20210483A (es) Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos
CL2019003636A1 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson.
MX388693B (es) Composiciones de nanoparticulas para terapia sostenida.
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
BR112014026424A2 (pt) composto, processo para produzir um composto de di-idrato, composto de benzotiofeno, método para prevenir e/ou tratar uma doença, e, composição farmacêutica
BR112019000130A2 (pt) formulação agrícola, formulação aquosa compreendendo a mesma, agente de tratamento agrícola, produto vegetal, método de tratamento de um alvo agrícola e método para reduzir a transmissão de uma doença fúngica de planta
MX391725B (es) Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.
BR112016024573A2 (pt) composições para deposição sobre superfícies biológicas
BR112015021057A2 (pt) método e aparelho para formar uma parte, e, parte formada a quente
BR112017025631A2 (pt) composições oftálmicas aquosas, método de induzir ou aumentar a formação de lágrima, método de formação de aglomerados de ciclosporina a e uso de ciclosporina a
BR112017021191A2 (pt) um extrato de indigo naturalis e um processo para preparar o mesmo
CL2010000749A1 (es) Polvo mesoporoso de oxido de zinc que tiene tamano promedio en numero de agregados de oxido de zinc de por lo menos 0,8 micrometros o por lo menos 1 micrometro; y metodo para producir dicho polvo.
MX2018016032A (es) Nuevo extracto de aquenio silybum marianum y usos del mismo en la dermatologia y dermocosmeticos.
BR112017024304A2 (pt) processo para a preparação de um extrato de cérebro animal
BR112018008089A2 (pt) composição aquosa para cuidados pessoais.
ECSP19018116A (es) 1–arilnaftiridin–3–carboxamidas 7–sustituidas y su uso
WO2018081183A3 (en) Maca compositions and methods of use
CL2020003374A1 (es) Composicion y metodo de cannabinoides para tratar el tept y/o la ansiedad
BR112015019084A2 (pt) métodos para aumentar o rendimento das culturas
MX2018011760A (es) Aducto de ciclodextrina-panobinostat.
IT201700107065A1 (it) Metodo per la distribuzione e/o l'aggiornamento di un database contente no fly zones a veicoli uav, e relativo veicolo
BR112017009811A2 (pt) composição e método para a modelagem de cabelo
MX379776B (es) Derivados de diamino piridina para usarse en el tratamiento de dermatitis atópica o psoriasis.
BR112012006267A2 (pt) processo para produzir partículas de substrato orgânico ligadas a nanopartículas ferromagnéticas comutáveis, partículas de substrato para diagnóstico, uso de nanopartículas ferromagnéticas comutáveis, e, medicamento para o tratamento de hipertermia no corpo humano ou animal

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.